San Diego biotech raises $90 million to treat infections in people with weak immune systems
SAN DIEGO — San Diego biotech company Amplyx Pharmaceuticals announced Tuesday that it has completed a $53 million extension to its Series C funding round, bringing the total for the round to $90 million.Sofinnova Venture Partners led the round, with participation from more than seven investment firms that had contributed in earlier rounds. Pfizer and Adage Capital Management joined the mix as new investors.The funds will mainly go toward testing two experimental drugs central to Amplyx’s mission — treating microbes that are usually harmless, but which can kill a person without a healthy immun...
The San Diego Union-Tribune
AI drug development platform raises $10 million in Series A
Stonewise, a Beijing-based platform that uses artificial intelligence (AI) for drug development, has raised nearly $10 million in Series A funding, the company said on Monday.Why it matters:The Covid-19 pandemic has cast a spotlight on the use of AI in treating and diagnosingdiseases, and its potential to quickly discover novel treatments for new and endemic infections.Covid-19, a new flu-like virus, was first reported in the central Chinese city of Wuhan in late December and has spread around the world, infecting nearly 170,000 people.Details: Stonewise’s latest round of funding was led by Lo...